Aytu Biopharma (AYTU) Total Current Liabilities (2011 - 2026)
Aytu Biopharma (AYTU) posted quarterly Total Current Liabilities of $60.0 million for Q1 2026, down 15.18% year-over-year from $70.7 million in Q1 2025, and down 8.53% quarter-over-quarter from $65.6 million in Q4 2025.
Aytu Biopharma (AYTU) Total Current Liabilities (2011 - 2026) Analysis & Trends
Aytu Biopharma (AYTU) has reported Total Current Liabilities for 16 consecutive years, with $60.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities fell 15.18% year-over-year to $60.0 million; the TTM figure through Mar 2026 stood at $60.0 million (down 15.18% YoY), while the FY2025 annual figure was $63.1 million, up 1.34% from the prior year.
- Total Current Liabilities declined to $60.0 million in Q1 2026 per AYTU's latest filing, from $65.6 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $85.4 million in Q1 2023 and bottomed at $60.0 million in Q1 2026.
- Historically, Total Current Liabilities has averaged $68.6 million across 5 years, with a median of $65.6 million in 2025.
- Annual changes were most pronounced in 2022 — Total Current Liabilities plunged 41.12% — and 2025, when it rose 7.74%.
- Aytu Biopharma's Total Current Liabilities stood at $67.1 million in 2022, then decreased by 4.41% to $64.2 million in 2023, then dropped by 0.22% to $64.0 million in 2024, then rose by 2.37% to $65.6 million in 2025, then fell by 8.53% to $60.0 million in 2026.
- Business Quant data shows AYTU's Total Current Liabilities at $60.0 million in Q1 2026, $65.6 million in Q4 2025, and $66.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | -8.38 Bn |
| 2 | Teva Pharmaceutical Industries | 43.02 Bn | 39.37 Bn | 2.15 Bn | 15.65 Bn |
| 3 | Zoetis | 31.47 Bn | 29.79 Bn | 1.05 Bn | 2.06 Bn |
| 4 | Takeda Pharmaceutical | 28.59 Bn | 22.79 Bn | 5.10 Bn | 17.34 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 6.35 Bn |
| 7 | Neurocrine Biosciences | 15.45 Bn | 15.06 Bn | 935.80 Mn | 874.50 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 1.85 Bn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | 1.79 Bn |
| 10 | Aytu Biopharma | 23.86 Mn | -2.85 Mn | 7.60 Mn | 59.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 59.97 Mn |
| Dec 31, 2025 | 65.56 Mn |
| Sep 30, 2025 | 65.99 Mn |
| Jun 30, 2025 | 63.06 Mn |
| Mar 31, 2025 | 70.71 Mn |
| Dec 31, 2024 | 64.05 Mn |
| Sep 30, 2024 | 61.25 Mn |
| Jun 30, 2024 | 62.23 Mn |
| Mar 31, 2024 | 83.69 Mn |
| Dec 31, 2023 | 64.19 Mn |
| Sep 30, 2023 | 65.46 Mn |
| Jun 30, 2023 | 69.02 Mn |
| Mar 31, 2023 | 85.42 Mn |
| Dec 31, 2022 | 67.15 Mn |
| Sep 30, 2022 | 73.20 Mn |
| Jun 30, 2022 | 64.44 Mn |
| Mar 31, 2022 | 80.36 Mn |
| Dec 31, 2021 | 100.57 Mn |
| Sep 30, 2021 | 98.00 Mn |
| Jun 30, 2021 | 109.44 Mn |